CAR-T Therapy

Legend Biotech Posts First Profitable Quarter as CARVYKTI Sales Reach $657 Million

The commercial surge gives the company cash runway to scale global rollouts and advance a next‑generation CAR‑T program toward a U.S. IND filing by year‑end 2026.